Skip to main content
. 2013 Oct 29;12:159. doi: 10.1186/1476-511X-12-159

Table 2.

Pooled relative risks of CVDs mortality for categorical and continuous analyses in subgroups

Sub-groups Triglyceride group (mg/dl)
 Per 1 mmol/L TG
<90
 90-146
 150-199
 ≥200
  
N* RR (95% CI) N* RR† N* RR (95% CI) N* RR (95% CI) N* RR (95% CI)
Age (year)
  <50
 3
 0.84 (0.74, 0.96)
 4
 1.00
 4
 1.21 (1.06, 1.40)
 3
 1.20 (0.94, 1.53)
 10
 1.11 (1.01, 1.22)
  ≥50
 7
 0.85 (0.68, 1.05)
 8
 1.00
 8
 1.08 (0.90, 1.30)
 5
 1.30 (0.99, 1.69)
 12
 1.15 (1.09, 1.22)
  P value
  
 0.956
  
  
  
 0.338
  
 0.664
  
 0.488
Gender
  Male
 5
 0.86 (0.67, 1.09)
 5
 1.00
 5
 1.06 (0.89, 1.30)
 5
 1.31 (1.12, 1.15)
 18
 1.10 (1.04, 1.15)
  Female
 3
 0.76 (0.64, 0.90)
 3
 1.00
 3
 1.37 (1.09, 1.71)
 2
 2.08 (1.44, 3.00)
 9
 1.40 (1.22, 1.59)
  Mixed
 4
 1.01 (0.65, 1.56)
 6
 1.00
 6
 1.14 (1.10, 1.31)
 4
 1.26 (0.99, 1.60)
 4
 1.16 (1.08, 1.25)
  P value
  
 0.416
  
  
  
 0.100
  
 0.023
  
 0.001
Follow-up (year)
  <12
 6
 0.81 (0.71, 0.91)
 6
 1.00
 6
 1.01 (0.84, 1.19)
 4
 1.25 (0.84, 1.84)
 11
 1.14 (1.06, 1.22)
  ≥12
 4
 0.79 (0.61, 1.02)
 4
 1.00
 6
 1.27 (1.13, 1.44)
 4
 1.25 (1.01, 1.54)
 11
 1.11 (1.02, 1.21)
  P value
  
 0.473
  
  
  
 0.025
  
 0.992
  
 0.694
Fast status
  Fast
 6
 0.89 (0.71, 1.12)
 7
 1.00
 7
 1.15 (0.98, 1.35)
 4
 1.42 (1.22, 1.64)
 10
 1.10 (1.04, 1.17)
  Nonfast
 3
 1.00 (0.65, 1.54)
 4
 1.00
 4
 1.14 (0.85, 1.46)
 4
 1.11 (0.85, 1.46)
 7
 1.12 (1.01, 1.23)
  Others§
 1
 0.80 (0.69, 0.93)
 1
 1.00
 1
 1.15 (0.90, 1.45)
 0
 -
 5
 1.19 (1.00, 1.41)
  P value
  
 0.646
  
  
  
 0.843
  
 0.122
  
 0.821
Geographic location
  Europe/America
 7
 0.86 (0.73, 1.01)
 8
 1.00
 8
 1.17 (1.00, 1.37)
 5
 1.22 (1.02, 1.55)
 18
 1.11 (1.05, 1.17)
  Asia-Pacific
 3
 0.80 (0.70, 0.92)
 4
 1.00
 4
 1.20 (0.93, 1.35)
 3
 1.20 (0.82, 1.77)
 4
 1.26 (1.05, 1.52)
  P value
  
 0.509
  
  
  
 0.729
  
 0.847
  
 0.205
Quality score
  <7
 4
 0.76 (0.65, 0.90)
 5
 1.00
 5
 1.01 (0.80, 1.29)
 4
 1.24 (0.91, 1.68)
 8
 1.16 (1.04, 1.29)
  7-9
 6
 0.92 (0.77, 1.05)
 7
 1.00
 7
 1.23 (1.09, 1.38)
 4
 1.25 (0.98, 1.60)
 14
 1.11 (1.04, 1.19)
  P value
  
 0.100
  
  
  
 0.167
  
 0.961
  
 0.509
Sample size
  <4000
 7
 0.84 (0.70, 1.02)
 7
 1.00
 7
 1.10 (0.91, 1.32)
 4
 1.49 (1.21, 1.80)
 10
 1.14 (1.06, 1.22)
  ≥4000
 3
 0.83 (0.71, 0.97)
 5
 1.00
 5
 1.18 (1.02, 1.38)
 4
 1.12 (0.84, 1.45)
 12
 1.13 (1.04, 1.22)
  P value
  
 0.910
  
  
  
 0.541
  
 0.100
  
 0.883
Free of CVDs at baseline
  Yes
 6
 0.85 (0.76, 0.96)
 7
 1.00
 7
 1.12 (0.92, 1.36)
 6
 1.20 (0.96, 1.50)
 13
 1.11 (1.04, 1.20)
  No
 4
 0.88 (0.67, 1.56)
 5
 1.00
 5
 1.16 (1.00, 1.34)
 2
 1.43 (1.16, 1.76)
 9
 1.16 (1.09, 1.24)
  P value
  
 0.832
  
  
  
 0.811
  
 0.265
  
 0.371
Adjustment
  Minimally
 4
 0.72 (0.55, 0.94)
 5
 1.00
 5
 1.44 (1.16, 1.78)
 4
 1.52 (1.14, 2.02)
 7
 1.15 (1.08, 1.22)
  Maximally
 4
 0.87 (0.77, 0.98)
 5
 1.00
 5
 1.24 (1.05, 1.46)
 4
 1.29 (1.01, 1.65)
 7
 1.05 (0.99, 1.11)
  P value
  
 0.207
  
  
  
 0.271
  
 0.398
  
 0.033
Adjustment for TC
  Yes
 4
 0.85 (0.77, 0.94)
 4
 1.00
 4
 1.24 (1.07, 1.43)
 3
 1.27 (0.94, 1.71)
 14
 1.09 (1.03, 1.16)
  No
 6
 0.82 (0.61, 1.09)
 8
 1.00
 8
 1.06 (0.89, 1.26)
 5
 1.25 (0.97, 1.61)
 8
 1.21 (1.10, 1.34)
  P value
  
 0.810
  
  
  
 0.169
  
 0.927
  
 0.078
Adjustment for HDL
  Yes
 3
 0.81 (0.72, 0.91)
 3
 1.00
 3
 1.23 (1.04, 1.47)
 1
 1.52 (1.14, 2.02)
 3
 1.10 (1.03, 1.19)
  No
 7
 0.84 (0.68, 1.04)
 9
 1.00
 9
 1.09 (0.94, 1.27)
 7
 1.21 (1.00, 1.47)
 19
 1.13 (1.06, 1.20)
  P value   0.734       0.313   0.200   0.679

*The number of cohorts.

†Reference group.

§Others included mixed and unknown ones.

RR, relative risk; CI, confidence interval; CVDs: cardiovascular diseases; HDL: high-density lipoprotein.

TG: triglycerides; TC: total cholesterol.

HHS Vulnerability Disclosure